[A Case of Recurrent Breast Cancer with Delayed Wound Healing Induced by Bevacizumab].
Gan To Kagaku Ryoho
; 51(3): 287-289, 2024 Mar.
Article
em Ja
| MEDLINE
| ID: mdl-38494810
ABSTRACT
Bevacizumab plus paclitaxel therapy for recurrent breast cancer did not prolong overall survival(OS)in clinical trials, but it was efficacious for treating life-threatening HER2-negative recurrent breast cancer. This regimen is often used in daily clinical practice by breast surgeons. However, bevacizumab therapy results in unique adverse events, of which proteinuria and hypertension are relatively frequent. Moreover, the symptoms often improve on reducing the dose or discontinuing the drug. In this case, bevacizumab administration caused delayed wound healing, making subsequent anticancer treatment difficult, and consequently we could not prolong the patient's life.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
Limite:
Female
/
Humans
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Ano de publicação:
2024
Tipo de documento:
Article